-
Oct 17, 2025, 05:26 AM
by
FDB Announces First MCP Server for AI Clinical Decision Support and Other Medication Workflow Automation
Full story
-
Oct 17, 2025, 05:26 AM
by
Full story
-
Oct 17, 2025, 05:26 AM
by
Brook.ai Secures $28 Million in Series B Funding,
Led by UMass Memorial Health and Morningside, to Accelerate Next Phase
of Growth and Innovation in Remote Care
Full story
-
Oct 17, 2025, 05:26 AM
by
Full story
-
Oct 17, 2025, 05:26 AM
by
Collaboration unites elluminate platform technology and ZS RBQM expertise to offer a fully integrated, data-driven approach to risk and quality management
Full story
-
Oct 16, 2025, 08:31 AM
by
Proscia®, a pathology AI company, will add AI biomarker detection for skin tissue to its Concentriq® software platform, empowering pathologists to drive efficiency and precision. Powered by Primaa, Cleo Skin* will strengthen Concentriq's lead in offering the industry’s broadest portfolio of AI solutions on a single platform.
Full story
-
Oct 16, 2025, 08:31 AM
by
InformedDNA and Know Your Lemons are combining their expertise in oncology, patient education, precision medicine and genetic counseling to provide personalized screening and care recommendations for those at various risks for breast cancer. The partnership extends Know Your Lemons’ mission to provide breast cancer education and guidance.
Full story
-
Oct 16, 2025, 08:31 AM
by
Aylward Enterprises, a recognized leader in oral solid dose (OSD) packaging automation, highlights two complementary bulk handling solutions engineered to optimize product transfer and inspection prior to feeding: the Bulk Product Conveyor (BPC) and the BPC Sorter. Designed to seamlessly integrate with upstream feeding systems, these accessories deliver reliable product transport, chip removal, and automated inspection, helping manufacturers maintain high throughput and product quality across pharmaceutical, nutraceutical, and healthcare operations.
Full story
-
Oct 16, 2025, 01:01 AM
by
User Not Found
Bio-IT World | Last month, uniQure announced promising results from their Phase I/II study of AMT-130, the company’s gene therapy to treat Huntington’s disease. A participant pool of 29 patients in the early stages of Huntington’s disease was categorized into two groups—low-dose and high-dose—and compared to a control group of 1,600 untreated Huntington’s patients at similar disease stages.
Full story
-
Oct 15, 2025, 09:29 AM
by
Syncell Inc. announced the deployment of its commercial Microscoop® Mint technology at two of Europe’s foremost research institutes.
Full story
-
Oct 15, 2025, 09:29 AM
by
Full story
-
Oct 15, 2025, 09:29 AM
by
Full story
-
Oct 15, 2025, 09:29 AM
by
• Combines single-organ, multi-organ, and higher-throughput configurations within one scalable platform
• Fully compatible with existing PhysioMimix accessories, validated protocols, consumables, and organ model kits for seamless workflow integration
Full story
-
Oct 15, 2025, 01:01 AM
by
User Not Found
Bio-IT World | Glycans, the complex sugar chains found at abnormally high levels on the surface of cancer cells, have historically been difficult to target effectively with traditional antibody therapies. One of the biggest reasons is that T cells can’t present glycans to B cells so they can make antibodies that bind strongly and stably to the target antigen.
Full story
-
Oct 14, 2025, 01:01 AM
by
User Not Found
Bio-IT World | The Target of Rapamycin (TOR) signaling pathway is a prime target for therapeutic development, since its dysregulation is implicated in promoting aging and a range of age-related diseases. By inhibiting TOR, the prescription medication rapamycin has been successfully used to prevent organ transplant rejection and treat certain cancers, but its use for anti-aging purposes in healthy individuals has yet to be approved by the Food and Drug Administration (FDA).
Full story
-
Oct 10, 2025, 16:41 PM
by
User Not Found
Bio-IT World | Researchers from Recursion are further developing their work on protein-ligand docking with a new digital tool: the Boltz-ABFE pipeline. This summer, with researchers from MIT, Recursion researchers released Boltz-2, an updated artificial intelligence model that can predict protein structure and binding affinity.
Full story
-
Oct 10, 2025, 08:06 AM
by
Alithea Genomics has announced the commercial launch of MERCURIUS™ Spheroid DRUG-seq, a novel, extraction-free RNA sequencing library preparation kit built for 3D spheroid models.
Full story
-
Oct 10, 2025, 08:06 AM
by
Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.
Full story
-
Oct 10, 2025, 01:01 AM
by
User Not Found
Bio-IT World | Over 10,000 rare diseases affect millions worldwide, yet fewer than 5% have treatments. Musician-turned-biotech founder Casey McPherson is rewriting the playbook for rare disease research and drug development, which he discusses in the latest episode of Trends from the Trenches.
Full story
-
Oct 8, 2025, 11:08 AM
by
Gifthealth, the patient access solution that unifies the prescription journey from provider to patient, today announced it has now served more than six million patients through its direct-to-patient (DTP) platform.
Full story